Skip to main content
editorial
. 2012 Nov 13;3(11):1264–1265. doi: 10.18632/oncotarget.748

Figure 1. Epigenetically targeting c-Myc and c-Myc-regulated genes for aggressive B-cell lymphoma therapy.

Figure 1

c-Myc plays a central role in aggressive B-cell lymphoma pathogenesis. c-Myc and c-Myc target miRNAs are regulated through histone modifications and can be epigenetically targeted by HDAC and PRC2 inhibitors for aggressive B-cell lymphoma therapy.